Delta-sleep-inducing peptide

From Retapedia, the free peptide encyclopedia
Medical disclaimer. This article is for informational purposes only and does not constitute medical advice. Consult a qualified clinician before considering any compound discussed below. See Retapedia : Medical disclaimer.

Delta-sleep-inducing peptide is a performance-enhancing peptide studied for its effects on physiological function. Delta-sleep-inducing peptide (DSIP) is a neuropeptide tied to animal EEG sleep activity; its human sleep role is weak. Shows preclinical antiepileptic activity.

Delta-sleep-inducing peptide (DSIP) is a neuropeptide that when infused into the mesodiencephalic ventricle of recipient rabbits induces spindle and delta EEG activity and reduced motor activities. As an unapproved research peptide with no regulatory approval for human therapeutic use, it is prohibited by WADA at all times under category S0 (non-approved substances).

Natty status
Delta-sleep-inducing peptide is classified as not natty. It is prohibited by WADA and most natural bodybuilding federations. Use places the athlete in the enhanced category. See § Natty status.
Contents [hide]
  1. 1 Overview
  2. 2 Mechanism of action
  3. 3 Reported effects
  4. 4 Natty status
  5. 5 Research
  6. 6 Related compounds
  7. 7 References
  8. 8 External links

Overview

Delta-sleep-inducing peptide (DSIP) is a neuropeptide that when infused into the mesodiencephalic ventricle of recipient rabbits induces spindle and delta EEG activity and reduced motor activities. As an unapproved research peptide with no regulatory approval for human therapeutic use, it is prohibited by WADA at all times under category S0 (non-approved substances).

Mechanism of action

A neuropeptide named for inducing delta EEG sleep activity in animals, though its own link to human sleep is weak and poorly characterized. Shows preclinical antiepileptic activity.

Reported effects

Effects reported in the literature and from preclinical models include:

  • DSIP and its analogues may help stabilize brain excitability and act as endogenous antiepileptics against generalized audiogenic convulsions in animal models. [1] Preclinical
  • Certain artificial DSIP structural analogues promote slow-wave sleep in rabbits and rats, though DSIP itself has a weak, poorly characterized direct link to sleep. [2] Preclinical

Evidence grades: FDA approved Phase III Phase II Phase I Preclinical Anecdotal

Natty status

See also: Peptide § Natty status

Delta-sleep-inducing peptide is classified as not natty. It appears on the WADA prohibited list and is banned by major natural bodybuilding federations.[3] Use of this compound places the athlete in the enhanced category rather than the natural category in competitive contexts.

Research

The peptide has been the subject of 3 studies and reference works collected on this site. The full bibliography is in § External links below.

Other peptides in this catalogue with overlapping mechanisms or status:

5-Amino-1MQ Not natty
Oral small-molecule NNMT inhibitor that raises NAD+ and S-adenosyl methionine to boost fat-cell energy expenditure. Studied only in rodents for fat loss; no human trials exist.
Epithalon Not natty
Marketed as an anti-aging peptide. In preclinical studies it boosts telomerase activity, supports the body's own melatonin production, and shows antioxidant effects. Human evidence is minimal.
CJC-1295 Not natty
Increases growth hormone and IGF-1 for 6+ days per injection. Improves body composition, muscle recovery, and fat metabolism. Weekly dosing.
BPC-157 Not natty
Speeds healing of tendons, ligaments, muscles, and gut. Reduces inflammation and muscle soreness. Minimizes scar tissue formation.

References

  1. ^ [Endogenous anticonvulsants: neuropeptide Y and delta sleep inducing peptide]. Review
  2. ^ Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Review
  3. a b World Anti-Doping Agency. (2026). Prohibited List 2026.

External links

Categories: Peptides | Performance-enhancing substances |

This page was last updated on July 17, 2026, at 16:19 (UTC).

Research last reviewed on July 17, 2026.

Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply.